<DOC>
	<DOCNO>NCT00859391</DOCNO>
	<brief_summary>This Phase 0 , Double-blind study ass effect vitro treatment gluten ALV003 placebo ingest CD Subjects .</brief_summary>
	<brief_title>Effects Gluten Digestion With ALV003</brief_title>
	<detailed_description>The primary objective study compare effect gluten treat ALV003 v placebo : - The clinical response symptom measurement oral challenge - The immune response measure ELISPOT test serology The secondary objective study - Describe immunotoxic epitope profile gluten digest ALV003 compare placebo</detailed_description>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Age 1875 year Well control Celiac Disease without flare symptom past 8 week History biopsy proven Celiac Disease Able willing complete symptom diary 3 day prior 3 day post gluten challenge Been gluten free diet 8 week prior study entry Have normal celiac serology ( anti tTG level &lt; 20 units/mL ) Uncontrolled complication celiac disease opinion Investigator would impact immune response , pose increase risk subject . ( example : like type 1 diabetes autoimmune disease ) Pregnant breast feed woman , subject childbearing potential use two method contraception Concomitant medication counter digestive enzyme , immunosuppressive therapy , anticoagulant , NSAIDs . Chronic medication wellcontrolled chronic condition allow . Clinically significant abnormal lab value , determine PI : Untreated active peptic ulcer disease , esophagitis , motility disorder gastrointestinal disease . Positive pregnancy test within 7 day prior study drug administration Known allergy hypersensitivity E.coli E.coli derive protein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Celiac Disease</keyword>
</DOC>